Where ALX Oncology Holdings Stands With Analysts
Portfolio Pulse from Benzinga Insights
ALX Oncology Holdings (NASDAQ:ALXO) has received positive analyst ratings in the last quarter, with 7 analysts offering a 12-month price target averaging $17.79, an 18.6% increase from the previous target of $15.00. The ratings include 4 bullish and 3 somewhat bullish, with a high target of $27.00 and a low of $10.00.
December 08, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology Holdings has seen a positive shift in analyst sentiment with an increased average price target of $17.79, suggesting a bullish outlook for the stock.
The increase in the average price target and the predominance of bullish ratings indicate that analysts expect the stock to perform well in the short term. This positive sentiment is likely to influence investors and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100